Safe and Effective in Humans
The ANP family of peptides consists of four natriuretic peptides produced by the heart that have well-known physiological effects such as salt excretion, diuresis and vasodilation. Because of these antihypertensive effects, they were first used in humans as a treatment for congestive heart failure. These peptides are commonly administered intravenously and have produced no known serious adverse effects.
New Mechanism for the Treatment of Cancer
KT-220, our initial drug candidate from the ANP family of peptides, regulates cell growth via inhibition of the mitogen-activated protein kinase (MAPK) pathway. As an endogenous peptide acting through a natural mechanism, KT-220 can produce broader anti-cancer activity than small molecules without the associated side effects. ANP peptides are designed by nature to inhibit the MAPK pathway by controlling initiation of the signaling cascade while synthetic drugs block only specific parts of the pathway. Supporting the inherent anti-cancer properties of ANP is the rarity of primary and metastatic cancers in the heart, where these peptides are at their highest concentrations. Kalos is optimizing their lead drug candidates to an even smaller chain of peptides.
Remarkable Anti-Cancer Activity
KT-220 demonstrated remarkably broad anti-cancer activity, including inhibition of pancreatic, lung, prostate, breast, ovarian, colon, and melanoma cells in culture and of pancreatic, breast, and lung cancer tumors in models of human cancer.
Please watch the video slideshow below...